Alterity Therapeutics Limited filed a Form 6-K on November 20, 2026, disclosing that shareholders approved the resignation of PricewaterhouseCoopers and the appointment of BDO Audit Pty Ltd as the company's independent registered public accounting firm, both effective November 20, 2026.
Key Highlights
- Auditor change approved: Shareholders voted on November 20, 2026 to accept PricewaterhouseCoopers' resignation and appoint BDO Audit Pty Ltd as successor auditor.
- Effective date: Both the resignation of PwC and the appointment of BDO Audit Pty Ltd took effect November 20, 2026.
- No adverse opinions: For fiscal years ended June 30, 2026 and June 30, 2025, PwC issued no adverse opinions, disclaimers of opinion, or qualified or modified audit reports.
- No disagreements reported: The company disclosed no disagreements with PwC on accounting principles, financial statement disclosures, or auditing scope during fiscal years ended June 30, 2026 and 2025, and through November 20, 2026.
- New engagement period: BDO Audit Pty Ltd is appointed as auditor for the financial year ending June 30, 2027.
- No prior consultations: According to the filing, neither the company nor anyone on its behalf consulted with BDO Audit Pty Ltd on accounting or auditing matters during the fiscal years ended June 30, 2026 and 2025, or through November 20, 2026.
Alterity Therapeutics Discloses Auditor Transition Following 2026 Annual General Meeting
Alterity Therapeutics Limited (NASDAQ:ATHE), an Australian-incorporated company headquartered at Level 15, 500 Collins Street, Melbourne, Victoria, filed a Form 6-K with the U.S. Securities and Exchange Commission on November 20, 2026, reporting a change in its certifying accountant. The report states that PricewaterhouseCoopers, referred to in the filing as the "Former Auditor" or "PwC," resigned as the company's independent registered public accounting firm effective November 20, 2026, following shareholder approval at the 2026 Annual General Meeting held that same day.
According to the filing, BDO Audit Pty Ltd, designated the "Successor Auditor," was appointed in place of PwC, also effective November 20, 2026, and will serve as the company's independent registered public accounting firm for the financial year ending June 30, 2027. The company disclosed that during the fiscal years ended June 30, 2026 and June 30, 2025, PwC's audit reports on the company's consolidated financial statements contained no adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
The filing further states that there were no disagreements, as defined under Item 16F(a)(1)(iv) of Form 20-F, between the company and PwC on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures during the covered periods and through November 20, 2026. The company also confirmed no "reportable events," as described in Item 16F(a)(1)(v) of Form 20-F, occurred during those periods. The company noted it provided PwC with a copy of the disclosures in the Form 6-K and requested a letter from PwC to the SEC regarding agreement with the statements; that letter, dated November 20, 2026, is furnished as Exhibit 99.1 to the filing. The Form 6-K was signed by Julian Babarczy, Chairman.
What Was Disclosed
Alterity Therapeutics Limited reported the shareholder-approved resignation of PricewaterhouseCoopers and the appointment of BDO Audit Pty Ltd as successor auditor, both effective November 20, 2026, with no prior disagreements or reportable events disclosed with the former auditor.




Please wait processing your request...